October 26, 2015
BC Platforms, a world leader in genomic data management solutions, today announced that it has signed a partnership agreement with Helsinki University Hospital to use its genomic management platform to integrate, analyze and interpret their extensive clinical and genealogy data with next-generation sequencing data to provide innovative, personalized treatment options for breast cancer patients at the hospital. As part of the agreement, BC Platforms will use its proprietary cloud-based BC|MERGE platform to carry out all of the core data management tasks including the data integration and interpretation, security and storage to establish a scalable process to utilize increasing amounts of genetic data at the hospital.
The molecular data and clinical patient data will be analyzed in conjunction with a disease predisposition algorithm for Breast Cancer, BOADICEA, developed by the University of Cambridge to enable more holistic clinical decision-making. Whilst the initial application is for cancer research, the platform can be applied widely to other disease areas.
Mr. Mikko Rotonen, Director, ICT Development at Helsinki University Hospital commented: “Helsinki University Hospital is committed to integrating molecular data alongside clinical data to become a leader in translational research in order to provide the best clinical outcomes for our patients. We are pleased to be working with BC Platforms, a leader in genomic software management systems to support us in achieving our vision which has the potential to revolutionize how we make clinical decisions for our patients in the future.”
Mr. Tero Silvola, Chief Executive Officer at BC Platforms, commented:
“As the field of next-generation sequencing has exploded there remains an unmet need for this data to be integrated into clinical decision making to provide better treatment options for patients. We are delighted to be collaborating with the Helsinki University Hospital Cancer Center, recognized internationally as leaders in providing innovative personalized treatments to cancer patients with some of the best treatment outcomes.”
About BC Platforms
BC Platforms is a world leader in providing powerful genomic data management solutions to address some of the biggest healthcare challenges today by leveraging the convergence of genomics and information technologies. Founded in 1997, the Company has a strong scientific heritage underpinned by 18 years of working in close collaboration with a network of leading researchers, developers, manufacturers and vendors. Our high performing genomic data management platform enables flexible data integration, secure analysis and interpretation of molecular and clinical information. BC Platforms’ vision is to revolutionize drug development and clinical decision-making to bring personalized medicines to patients.
Our management team consists of industry leaders with over 90 years of combined experience in life sciences, computational biology and industrial technology. We currently provide solutions to over 50 leading international institutions in 18 countries including top-tier academic and hospital research groups, major pharmaceutical and agricultural companies. BC Platforms has global operations with its research and development located in Helsinki, Finland, and sales and marketing based in Basel, London, Boston, and Vancouver.
About Helsinki University Hospital
The Hospital District of Helsinki and Uusimaa and University Hospital Helsinki – is a Joint Authority formed by 24 municipalities. The aim is to offer patients in all member municipalities a timely and equal access to specialized medical care.
Functioning as part of HUS, Helsinki University Hospital HUH is nationally responsible for treating severe and rare illnesses and ones calling for special expertise and technology.
Comprehensive Cancer Center is a new department that opened on January 1, 2014. It handles all oncological treatments at HUH. The department was busier than ever in 2014, treating 21,548 individual patients in the course of the year. As its name states, the Comprehensive Cancer Center provides a full range of services in cancer care, including the development of support functions to ensure a high standard of care.